PolyNovo receives BARDA funding for Pivotal Trial

14 July 2020

PolyNovo is pleased to announce it has received funding of $15M USD from BARDA to support the Pivotal trial program of NovoSorb BTM. PolyNovo will make a modest co-funding and “in kind” contribution to the trial with the final budget to be announced after US FDA approval.

The NovoSorb BTM trial will gather extensive data on the effectiveness of NovoSorb BTM in the treatment of full thickness burns enabling PolyNovo to apply for PMA approval from the US FDA for this treatment indication. Outside of the US NovoSorb BTM is already approved for use on full thickness burns.

Managing Director, Paul Brennan said, “We appreciate BARDA’s ongoing commitment to NovoSorb BTM in funding this trial. Their substantial non-dilutive funding for this and other programs better enables PolyNovo to bring our innovative, life saving products to the US and the rest of the world.”

Read the ASX release. 


News & opinion

Member Directory